Radiopharm Theranostics (ASX: RAD) doses first patient with PD-L1 nanobody for lung cancer trial

July 10, 2024 01:14 PM AEST | By Sonal Goyal

Radiopharm Theranostics (ASX: RAD) doses first patient with PD-L1 nanobody for lung cancer trial — Image source: Company update

Recent News

TCL CSOT Highlights IJP OLED Innovations at the Omdia Korea Display Co...

Oil Faces Largest Weekly Loss Amid Supply and Demand Concerns

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indicat...

Gold Breaks New Record Amid Rising Global Uncertainty

Highlights

In a Phase 1 therapeutic non-small cell lung cancer (NSCLC) trial, the first patient has been dosed.

The first patient was dosed at the Wollongong Hospital, New South Wales.

The first-in-human trial aims to evaluate the safety and tolerability of ¹⁷⁷Lu-RAD 204 in individuals diagnosed with NSCLC and tested positive for PD-L1.

Radiopharm Theranostics Limited (ASX: RAD) has achieved a significant milestone in its efforts to develop transformative oncology radiotherapeutics. The company successfully administered the first therapeutic dose in the Phase 1 trial of RAD 204, a proprietary nanobody targeting PD-L1 (programmed death-ligand 1), which is commonly expressed in NSCLC.

The first patient was dosed at Wollongong Hospital in New South Wales. This important study is being conducted across several sites in Australia, including Hollywood Private Hospital in Western Australia, Princess Alexandra Hospital in Queensland, and Wollongong Hospital.

About the study

The title of the study is-

Data source: Company update

This trial is a first-in-human dose escalation trial of ¹⁷⁷Lu-RAD 204. It aims to assess the preliminary efficacy and safety of ¹⁷⁷Lu-RAD 204 in PD-L1-positive patients with metastatic NSCLC.

In the Phase 1 diagnostic study, 16 NSCLC patients were dosed. The results were promising, indicating that the diagnostic procedure had acceptable dosimetry, was safe, and showed significant potential of ¹⁷⁷Lu-RAD 204 in treating advanced NSCLC.

RAD shares were trading 2.86% higher at AUD 0.036 apiece at the time of writing on 10 July 2024.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.